SCHEMBL15440671

SCHEMBL15440671

c1ccc2c(c1)cnn2-c1cnc2[nH]ccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 6/20 0.48
AXL P30530 2/20 0.48
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
LRRK2 Q5S007 2/20 0.41
NUDT1 P36639 2/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
MAPK8 P45983 2/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
CDK7 P50613 2/20 0.39
CCNT1 O60563 1/20 0.39
CCND1 P24385 1/20 0.39
CCNC P24863 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13052911 0.74 CYP11B2 (0.55) CYP11B1CYP11B2LRRK2MGAMGAA
SCHEMBL16720315 0.72 CDK8 (0.51) CDK8AXLSLC6A2SLC6A4SLC6A3
SCHEMBL19961720 0.72 RAB9A (0.61) CYP11B1CYP11B2LRRK2MAPK9MAPK10
SCHEMBL15562322 0.71 CDK8 (0.46) CDK8AXLSLC6A2SLC6A4SLC6A3
SCHEMBL729956 0.70 KDM4E (0.56) CYP11B1CYP11B2LRRK2MGAMGAA
SCHEMBL30270004 0.70 KDM4E (0.56) CYP11B1CYP11B2LRRK2MGAMGAA
SCHEMBL100777 0.70 CCNK (0.49) CDK8AXLLRRK2NUDT1MAPK8
SCHEMBL21851736 0.70 CYP11B2 (0.51) CYP11B1CYP11B2LRRK2MGAMGAA
SCHEMBL3347164 0.70 CDK8 (0.49) CDK8AXLSLC6A2SLC6A4SLC6A3
SCHEMBL27767838 0.70 PIK3CA (0.44) CDK8AXLSLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 CDK8 572/4885AXL 1265/4885CYP11B1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.